Validation of a quick three-dimensional dose verification system for pre-treatment IMRT QA.
In this study, we evaluated the dosimetric performance of the three-dimensional (3D) dose verification system, COMPASS version 3 (IBA Dosimetry, GmbH, Germany). The COMPASS has the function of a dedicated beam modeling and dose calculation. It is able to reconstruct 3D dose distributions on patient CT images, using the incident fluence from a linear accelerator measured with the MatriXX 2D array (IBA Dosimetry). The dose profiles measured with various multi-leaf collimator (MLC) test patterns for the COMPASS were checked by comparison with those of EDR2 (Eastman Kodak, Rochester, NY) films and Monte Carlo (MC) simulations. The COMPASS was also used for dose verification in clinical intensity-modulated radiation therapy (IMRT) plans for head and neck cases. The dose distributions were compared with those measured by 3DVH (Sun Nuclear, Melbourne, FL) and MC. In addition, the quality assurance (QA) times among the COMPASS, 3DVH, and EDR2 were compared. For MLC test patterns, the COMPASS dose profiles agreed within 3 % with those of EDR2 films and MC simulations. The physical resolution of the COMPASS detectors was lower than that of film, but the dose resolution for MLC patterns was comparable to that of film. In clinical plans, the dose-volume-histograms were equal for all systems. The average QA times of the COMPASS, 3DVH, and EDR2 film were 40.1, 59.4, and 121.4 min, respectively. The COMPASS system provides fast and reliable 3D dose verification for clinical IMRT QA. The COMPASS QA process does not require phantom plans. Therefore, it allows a simple QA workflow.